Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Teva
Cipla
Harvard Business School
Colorcon
Daiichi Sankyo
Baxter
Covington
Fuji

Generated: April 23, 2018

DrugPatentWatch Database Preview

ANSOLYSEN Drug Profile

« Back to Dashboard

Which patents cover Ansolysen, and what generic alternatives are available?

Ansolysen is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in ANSOLYSEN is pentolinium tartrate. Additional details are available on the pentolinium tartrate profile page.
Drug patent expirations by year for ANSOLYSEN
Medical Subject Heading (MeSH) Categories for ANSOLYSEN
Synonyms for ANSOLYSEN
1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate
1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium; 2,3,4-trihydroxy-4-oxobutanoate
1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium; bis(3-carboxy-2,3-dihydroxypropanoate)
1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium;(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate
1,1'-Pentamethylenebis(1-methylpyrrolidinium hydrogen tartrate)
1,1'-Pentamethylenebis(1-methylpyrrolidinium tartrate)
1,1'-pentane-1,5-diylbis(1-methylpyrrolidinium) bis[(2R,3R)-3-carboxy-2,3-dihydroxypropanoate]
52-62-0
56614-93-8
953357GACY
AC1L1L9Q
AC1NWAY7
AC1Q76K9
AKOS024319549
AKOS026750069
Ambap52-62-0
Ansolysen bitartrate
Ansolysen tartrate
Butanoic acid, 2,3-dihydroxy- (2R,3R)-, ion(1-), 1,1'-(1,5-pentanediyl)bis(1-methylpyrrolidinium) (2:1)
CA010524
CCG-220188
CCG-222192
CCG-39059
CHEBI:55326
CHEMBL118902
CHEMBL1318287
EINECS 200-146-7
EU-0100888
HE071364
HMS1568F17
HMS1922M12
HMS2095F17
HMS3262B18
HMS502L14
HY-B1219
LP00888
LS-138467
m& b 2050a
MB 2050A
MCULE-6382957613
MolPort-006-110-088
NCGC00016191-02
NCGC00016191-03
NCGC00094207-01
NCGC00094207-02
NCGC00094207-03
NCGC00095085-01
NCGC00095085-02
NCGC00261573-01
NSC-759890
NSC759890
P 3520
Pendine
Pentalinium tartrate
Pentamethylene-1,5-bis(1'-methylpyrrolidinium tartrate)
Pentapyrrolidium bitartrate
Pentilium
pentolineum tartrate
Pentolinio tartrato
Pentolinio tartrato [DCIT]
Pentolinium (tartrate)
Pentolinium bitartrate
Pentolinium di[L(+)-tartrate]
Pentolinium ditartrate
PENTOLINIUM TARTRATE
Pentolinium tartrate [BAN]
Pentolinium tartrate [NF]
Pentolonii tartras
Pentolonii tartras [INN-Latin]
Pentolonium tartrate
Pentoloniumtartrat
PENTOLONUM BITARTRATE
Pharmakon1600-01503933
Prestwick_918
Pyrrolidinium 1,1'-(1,5-pentanediyl)bis-(1-methyl-, (R-(R*,R*))-2,3-dihydroxybutanedioate
Pyrrolidinium, 1,1'-(1,5-pentanediyl)bis(1-methyl-, salt with (R-(R*,R*))-2,3-dihydroxybutanedioic acid (1:2)
Pyrrolidinium, 1,1'-(1,5-pentanediyl)bis(1-methyl)-, salt with (R-(R*,R*))-2,3-dihydroxybutanedioic acid (1:2)
Pyrrolidinium, 1,1'-pentamethylenebis(1-methyl-, tartrate (1:2)
Recuryl
SCHEMBL3032406
SCHEMBL309647
SPECTRUM1503933
SR-01000075173
SR-01000075173-1
ST50411507
Tartaric acid, ion(1-), 1,1'-pentamethylenebis(1-methylpyrrolidinium) (2:1)
Tartrate de pentolonium
Tartrate de pentolonium [INN-French]
Tartrato de pentolonio
Tartrato de pentolonio [INN-Spanish]
Tensilest
Tox21_500888
UNII-953357GACY

US Patents and Regulatory Information for ANSOLYSEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Ayerst ANSOLYSEN pentolinium tartrate INJECTABLE;INJECTION 009372-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chubb
Express Scripts
Medtronic
Teva
Queensland Health
Fish and Richardson
Healthtrust
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.